Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04437160 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT04437160 · ClinicalTrials.gov record · last posted 2020-06-18

Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

Name: Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy — clinical trial record (NCT04437160)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorChinese Academy of Medical Sciences

Started2020-02-01

View on ClinicalTrials.gov ↗

Record status

This record was last updated June 18, 2020 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.

from the ClinicalTrials.gov record

This study will evaluate the efficacy and safety of antharcycline-based adjuvant chemotherapy compared with observation in triple negative breast cancer (TNBC) patients with residual invasive disease after platinum and taxanes based neoadjuvant chemotherapy.

Trial Details

NCT Number	NCT04437160
Lead Sponsor	Chinese Academy of Medical Sciences
Conditions	Triple Negative Breast Cancer
Enrollment	286 participants
Start Date	2020-02-01
Primary Completion	2026-01 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2020-06-18